Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$913 Mln
Revenue (TTM)
$23 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
-0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
53,296,950
CFO
$-180.21 Mln
EBITDA
$-253.51 Mln
Net Profit
$-278.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
| -- | -13.7 | -- | -- | 78.0 | 4.4 | 23.2 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
| -70.4 | -57.8 | -45.4 | 52.9 | 61.0 | -20.1 | 6.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akoustis Technologies (AKTS)
|
17.4 | 912.5 | 1.5 | -44.0 | -186.6 | 60.7 | -- | 0.0 |
| 81.4 | 6,385.4 | 1,442.1 | 107.6 | 10.2 | 12.5 | 60.6 | 7.3 | |
| 332.3 | 11,343.3 | 1,798.8 | 148.4 | 6.6 | 11.6 | 77.1 | 8.8 | |
| 103.9 | 6,617.1 | 455.7 | -38.2 | -9.6 | -7.9 | -- | 10.4 | |
| 177.4 | 6,159.8 | 3,738.3 | 312.8 | 11.1 | 16.7 | 20.7 | 3.2 | |
| 346.5 | 8,059.7 | 2,386.3 | -71.7 | 1.6 | -3 | -- | 3.3 | |
| 547.8 | 6,102.2 | 1,114.1 | 187.4 | 20.6 | 29.7 | 35 | 9.4 | |
| 184.0 | 11,861.3 | 5,934.5 | 279.5 | 11.8 | 4.3 | 42.3 | 1.7 | |
| 155.6 | 6,453.0 | 407.7 | 118.6 | 21.6 | 18.5 | 54.3 | 10.5 | |
| 277.5 | 12,512.9 | 23,510.9 | 640.2 | 5.3 | 12.8 | 20.1 | 2.4 |
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop... radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts. Address: 17 Drydock Avenue, Boston, MA, United States, 02210 Read more
Founder, President, CEO & Director
Mr. Jeffrey B. Shealy
Founder, President, CEO & Director
Mr. Jeffrey B. Shealy
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Akoustis Technologies Inc (AKTS) is $17.37 (NASDAQ) as of 02-Apr-2026 16:12 EDT. Akoustis Technologies Inc (AKTS) has given a return of 78% in the last 3 years.
Since, TTM earnings of Akoustis Technologies Inc (AKTS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
The 52-week high and low of Akoustis Technologies Inc (AKTS) are Rs 23.36 and Rs 14.72 as of 03-Apr-2026.
Akoustis Technologies Inc (AKTS) has a market capitalisation of $ 913 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Akoustis Technologies Inc (AKTS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.30
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.